Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    21323176 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
Conditions: Diphtheria, Tetanus, Pertussis, Poliomyelitis & Haemophilus Influenzae Type b Disease;   Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines
Intervention: Biological: GSK Biologicals' combined DTPa-IPV/Hib vaccine
2 Completed Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine
Conditions: Haemophilus Influenzae Type b;   Diphtheria;   Tetanus;   Poliomyelitis;   Acellular Pertussis
Interventions: Biological: DTPa-HBV-IPV/Hib;   Biological: DTPa-IPV/Hib vaccine
3 Completed A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
Condition: Infections, Rotavirus
Intervention: Biological: Rotavirus

Indicates status has not been verified in more than two years